



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology (Oral – Anaplastic Lymphoma Kinase [ALK]-Positive Agent) – Alunbrig Prior Authorization Policy

- Alunbrig® (brigatinib tablets – ARIAD/Takeda)

**REVIEW DATE:** 07/30/2025

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Alunbrig, a kinase inhibitor, is indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive, metastatic **non-small cell lung cancer (NSCLC)** in adults, as detected by an FDA-approved test.<sup>1</sup>

### Guidelines

Alunbrig is addressed in National Comprehensive Cancer Network (NCCN) guidelines:<sup>2-5</sup>

- **Histiocytic Neoplasms:** Guidelines (version 1.2025 – June 20, 2025) recommend Alunbrig as a "Useful in Certain Circumstances" treatment option for ALK-positive Erdheim-Chester disease (category 2A).<sup>3</sup>
- **Inflammatory Myofibroblastic Tumor (IMT):** NCCN Soft Tissue Sarcoma guidelines (version 1.2025 – May 2, 2025) recommend Alunbrig as a "Preferred" treatment option for IMT with ALK translocation (category 2A). The

NCCN Uterine Neoplasms guidelines (version 3.2025 – March 7, 2025) recommend Alunbrig as “Useful in Certain Circumstances” for first-line therapy for advanced, recurrent/metastatic, or inoperable IMT with ALK translocation for uterine sarcoma (category 2A).<sup>5,6</sup>

- **NSCLC:** Guidelines (version 7.2025 – July 10, 2025) recommend testing for *ALK* rearrangements in eligible patients with NSCLC.<sup>4</sup> If *ALK* rearrangement is discovered prior to first-line systemic therapy, Alunbrig is a “Preferred” first-line treatment option (category 1). If *ALK* rearrangement is discovered during first-line systemic therapy, options are to complete the planned systemic therapy (including maintenance therapy) or to interrupt the systemic therapy and treat with Alunbrig (“Preferred”, category 2A) or another *ALK* inhibitor. NCCN recommendations for patients with disease progression often include continuing the first-line targeted therapy, depending on type of progression.
- **T-Cell Lymphomas:** Guidelines (version 2.2025 – May 28, 2025) recommend Alunbrig for *ALK*-positive anaplastic large-cell lymphoma (ALCL) under “other recommended regimens” (category 2A) for initial palliative-intent therapy and for second-line/subsequent therapy (regardless of intention to transplant).<sup>7</sup>

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Alunbrig. All approvals are provided for the duration noted below.

- **Alunbrig® (brigatinib tablets - ARIAD/Takeda)**  
**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

## **FDA-Approved Indication**

1. **Non-Small Cell Lung Cancer.** Approve for 1 year if the patients meets ALL of the following (A, B, C, and D):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient has advanced or metastatic disease; AND
  - C)** Patient has anaplastic lymphoma kinase (*ALK*)-positive disease; AND
  - D)** The mutation was detected by an approved test.

## **Other Uses with Supportive Evidence**

2. **Erdheim-Chester Disease.** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A)** Patient is  $\geq 18$  years of age; AND
  - B)** Patient has anaplastic lymphoma kinase (*ALK*) rearrangement/fusion-positive disease.
3. **Inflammatory Myofibroblastic Tumor.** Approve for 1 year if the patients meets ALL of the following (A, B, and C):
  - A)** Patient is  $\geq 18$  years of age; AND

**B)** Patient has anaplastic lymphoma kinase (ALK)-positive disease; AND

**C)** Patient meets ONE of the following (i or ii):

- i. Patient has advanced, recurrent, or metastatic disease; OR
- ii. The tumor is inoperable.

**4. Peripheral T-Cell Lymphomas.** Approve for 1 year if the patient meets BOTH of the following (A and B):

A) Patient is  $\geq$  18 years of age; AND

B) Patient has anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

## CONDITIONS NOT COVERED

- **Alunbrig® (brigatinib tablets - ARIAD/Takeda)**

**is(are) considered not medically necessary for ANY other use(s); criteria will be updated as new published data are available.**

## REFERENCES

1. Alunbrig® tablets [prescribing information]. Cambridge, MA: ARIAD/Takeda; February 2022.
2. The NCCN Drugs & Biologics Compendium. © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 28, 2025. Search terms: brigatinib.
3. The NCCN Histiocytic Neoplasms Clinical Practice Guidelines in Oncology (version 1.2025 – June 20, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 28, 2025.
4. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 7.2025 – July 10, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 28, 2025.
5. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (version 1.2025 – May 2, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 28, 2025.
6. The NCCN Uterine Neoplasms Clinical Practice Guidelines in Oncology (version 3.2025 – March 7, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 28, 2025.
7. The NCCN T-Cell Lymphomas Clinical Practice Guidelines in Oncology (version 2.2025 – May 28, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 28, 2025.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes	07/12/2023
Annual Revision	<b>Peripheral T-Cell Lymphomas:</b> Added new approval condition and criterion under "Other Uses with Supportive Evidence".	08/07/2024
Update	04/21/2025: The policy name was changed from "Oncology – Alunbrig PA Policy" to "Oncology (Oral – Anaplastic Lymphoma Kinase [ALK]-Positive Agent) – Alunbrig PA Policy".	N/A
Annual Revision	No criteria changes	07/30/2025

N/A – Not applicable.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.